Summit Therapeutics partners with AstraZeneca, Daiichi Sankyo to test ivonescimab with Datroway in solid tumors

Bitget2026/10/02 06:30

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Summit Therapeutics entered a clinical trial collaboration with AstraZeneca and Daiichi Sankyo to test ivonescimab with Datroway in solid tumors.
Parties plan to start with a Phase III trial in first-line triple-negative breast cancer, targeting an expansion into breast and lung cancer.
AstraZeneca or Daiichi Sankyo will sponsor the studies; all three companies will share trial costs.
Each partner will supply its own drug for the trials, retaining development and commercial rights to its respective medicine.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Summit Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261001197318) on October 02, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Summit Therapeutics partners with AstraZeneca, Daiichi Sankyo to test ivonescimab with Datroway in solid tumors

You may also like

Crypto prices